
Dr. Emily Podany links food deserts to aggressive breast cancer mutations and shorter survival, stressing the need for social determinant screening.

Dr. Emily Podany links food deserts to aggressive breast cancer mutations and shorter survival, stressing the need for social determinant screening.

Dr. Paolo Tarantino discusses the importance of strategic sequencing and drug-specific prophylaxis to optimize ADC therapy in breast cancer.

KEYNOTE-522 trial data shows adding Keytruda to chemotherapy drastically improves long-term survival for high-risk, early-stage TNBC.

A cancer survivor’s wife created a life transition binder during his treatment to organize medical, financial and household information to access details in emergencies.

Dr. Maurie Markman, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

Two-time acute myeloid leukemia survivor Amanda Ferraro teamed up with CURE to share the 10 things that helped her get through cancer treatment — offering hope, strength and support for others navigating their own journey.

Michele Kranz, discussed how oncology nurse navigators like herself support patients with cancer through education, advocacy and care coordination.

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in cancer survivors.

Oncology dietitians shared smoothie and turmeric latte recipes to help patients with breast cancer manage nutrition during treatment.

MD Anderson’s trial uses psilocybin and psychotherapy to treat cancer-related anxiety, helping patients thrive through neuroplasticity.

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness.

Dr. Samyukta Mullangi shares how AI can help patients understand oncology visits, ask better questions, and feel more engaged in their care.

CURE spoke with Dr. Michael E. Kasper, medical director of radiation oncology at the Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital.

Rutgers researchers find tactical problem-solving significantly lowers anxiety and empowers young adult cancer patients to manage developmental stressors.

A patient details diagnosis, transplant treatment and the complex path to recovery and survivorship after leukemia.

KRAS was long thought undruggable in cancer until scientists discovered a hidden binding pocket in mutant KRAS, leading to targeted therapies.

Dr. Ramy Sedhom discusses how embedded psychosocial care in oncology may improve access, engagement and emotional support during cancer care.

Urologist Dr. Susan MacDonald breaks down the differences between soft tissue and blood cancers while highlighting common and rare disease types.

MD Anderson’s Dr. Wendy Woodward discusses breath-hold techniques, insurance hurdles, and proton therapy’s role in reducing radiation cardiac toxicity.

Dr. Tony Anderson speaks about fertility preservation options for men and women before cancer treatment, emphasizing early testing and timely referral.

Dr. Tony Anderson discusses key questions after a cancer diagnosis and fertility planning.

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.

Lauren Yerkes, founder of POST SWIM, discusses the jarring shift to breast cancer survivorship and the daily practice of reclaiming body confidence.

The ATOMIC Trial shows how adding immunotherapy to chemotherapy may reduce recurrence risk and improve outcomes in stage III dMMR colon cancer.

The National Ovarian Cancer Coalition (NOCC) delivers free meals to ovarian cancer patients, easing treatment burdens and supporting caregivers nationwide.

Researchers identified gut microbiome markers that predict melanoma return after surgery, allowing doctors to personalize immunotherapy for patients.

Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with mostly mild side effects.

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite loss and digestive issues.